Data Supplement from Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?
Christos Hatzis, Philippe Lucien Bedard, Nicolai J. Birkbak, Andrew H. Beck, Hugo J.W.L. Aerts, David F. Stern, Leming M. Shi, Robert C. Clarke, John Quackenbush, Benjamin Haibe‐Kains · 2023
Supplementary Table 1 reporting the main steps in the experimental protocol used in the CGP and CCLE studies. Different options were used across studies for most steps, including detection assay, quality assurance of screening plates, controls, and measures of drug potency (IC50), which are further described in Supplementary Information.